Transcription of MOH CLINICAL PRACTICE GUIDELINES 2/2016
{{id}} {{{paragraph}}}
1 MOH CLINICAL PRACTICE GUIDELINES 2/2016 LIPIDSEXECUTIVE SUMMARYC hapter of Family Medicine PhysiciansAcademy of Medicine, SingaporeCollege of Family Physicians, SingaporeSingapore Cardiac SocietyChapter of EndocrinologistsChapter of General PhysiciansCollege of Physicians, SingaporeEndocrine & Metabolic Society of SingaporeContents PageIntroduction and how to use this document 2 Lipids in coronary artery disease 4 Classification & screening for dyslipidemia 4 Risk assessment of CAD in dyslipidemia 6 Target lipid levels 8 Lifestyle changes 10 Drug therapy 12 Special considerations 16 Quality indicators for lipid management 19 Levels of evidence and grades of recommendation 262 EXECUTIVE SUMMARY OF RECOMMENDATIONS IntroductionThis is the executive summary of the MOH CLINICAL PRACTICE GUIDELINES (CPG) on Lipids.
• NT-proBNP N-terminal prohormone of brain natriuretic peptide • TC Total cholesterol • TG Triglyceride • VLDL Very low density lipoprotein • FH Familial Hypercholesterolemia. 4 Lipids in coronary artery disease Blood lipid levels are important risk factors for CAD. The relationship between CAD and
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}